PDS Biotechnology Corp.
(NASDAQ : PDSB)

( )
PDSB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.08%147.000.7%$951.24m
PFEPfizer Inc. -0.61%36.170.9%$850.59m
ABBVAbbVie, Inc. -0.46%86.881.9%$688.82m
MRKMerck & Co., Inc. -1.05%81.890.7%$684.35m
BMYBristol-Myers Squibb Co. 0.30%59.891.0%$656.68m
LLYEli Lilly & Co. -1.25%146.251.1%$550.56m
AZNAstraZeneca Plc 0.66%55.111.2%$255.78m
NVSNovartis AG 0.00%87.050.2%$172.65m
GSKGlaxoSmithKline Plc -1.15%37.430.2%$110.48m
NVONovo Nordisk A/S 1.52%70.220.1%$61.00m
RGENRepligen Corp. 2.25%150.597.1%$49.91m
RPRXRoyalty Pharma Plc 1.94%42.010.2%$48.37m
SNYSanofi -0.98%50.500.2%$44.87m
OPKOPKO Health, Inc. 7.86%3.4311.2%$38.15m
TPTXTurning Point Therapeutics, Inc. -0.87%88.550.0%$36.59m

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.